Gilead Subsidiary Wins Louisiana Hep C Drug Subscription Model Contract

Updated Story The Louisiana Department of Health picked Gilead subsidiary Asegua Therapeutics to fulfill its first-in-the nation subscription model to provide hepatitis C drugs to state Medicaid and corrections populations, the department announced Tuesday (March 26). If a contract is signed, Gilead will provide an unlimited supply of its authorized generic of Epclusa over five years for a flat fee. Two other companies, AbbVie and Merck, had also submitted bids . “We were extremely pleased that three...